T39274
Lumasiran sodium
TargetMol
DESCRIPTION
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, targets glycolate oxidase to reduce hepatic oxalate production, thereby reducing urinary oxalate excretion. This compound shows promise in addressing the underlying cause of progressive kidney failure in individuals with primary hyperoxaluria type 1 (PH1).
DETAILS
- Cas: 1834612-06-4
- Purity: 98%
- Category: Compound
Lead Time: 4 - 5 weeks
Sign in to view pricingEquivalent Items
| ... Loading